Related Experiment Video
Updated: Aug 14, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Advances in targeted therapy and immunotherapy for melanoma (Review)
1No. 4 Research Laboratory, Shanghai Institute of Biological Products Co., Ltd., Shanghai 200051, P.R. China.
Abstract:
Melanoma is the most aggressive and deadly type of skin cancer and is known for its poor prognosis as soon as metastasis occurs. Since 2011, new and effective therapies for metastatic melanoma have emerged, with US Food and Drug Administration approval of multiple targeted agents, such as V-Raf murine sarcoma viral oncogene homolog B1/mitogen-activated protein kinase kinase inhibitors and multiple immunotherapy agents, such as cytotoxic T lymphocyte-associated protein 4 and anti-programmed cell death protein 1/ligand 1 blockade. Based on insight into the respective advantages of the above two strategies, the present article provided a review of clinical trials of the application of targeted therapy and immunotherapy, as well as novel approaches of their combinations for the treatment of metastatic melanoma in recent years, with a focus on upcoming initiatives to improve the efficacy of these treatment approaches for metastatic melanoma.
Insights
New targeted therapies and immunotherapies have emerged for metastatic melanoma. This review examines clinical trials of these treatments and their combinations to improve outcomes for advanced skin cancer.
Area of Science:
- Oncology
- Dermatology
- Cancer Research
Background:
- Melanoma is an aggressive skin cancer with a poor prognosis upon metastasis.
- Recent advancements include FDA-approved targeted agents (BRAF/MEK inhibitors) and immunotherapies (CTLA-4, PD-1/PD-L1 blockade).
Purpose of the Study:
- To review clinical trials of targeted therapy and immunotherapy for metastatic melanoma.
- To explore novel combination approaches and upcoming strategies to enhance treatment efficacy.
Main Methods:
- Review of recent clinical trials and literature on metastatic melanoma treatments.
- Analysis of targeted therapy, immunotherapy, and combination strategies.
Main Results:
- Significant progress in metastatic melanoma treatment since 2011 with new targeted and immune agents.
- Emerging data on the efficacy of combining targeted therapy and immunotherapy.
Conclusions:
- Combination therapies hold promise for improving outcomes in metastatic melanoma.
- Ongoing research focuses on optimizing these treatments for better patient survival.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

